Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 109-113

  Liu, Peng ^a   Li, Jianyong ^a   Lu, Hua ^a   Xu, Bei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Egr 1; Invasion; Leukemia; Thalidomide

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; MATRIGEL; MESSENGER RNA; SMALL INTERFERING RNA; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; UMBILICAL VEIN; UPREGULATION;

CELL MOVEMENT; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; THALIDOMIDE; UP-REGULATION;

EID: 59249099510     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802588352     Document Type: Article

References (26)

1. Franks, M. E., Macpherson, G. R. and Figg, W. D. (2004) Thalidomide. Lancet, 363, pp. 1802-1811.
2. Ribatti, D. and Vacca, A. (2005) Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia, 19, pp. 1525-1531.
3. Baek, S. J., Kim, J. S., Moore, S. M., Lee, S. H., Martinez, J. and Eling, T. E. (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol, 67, pp. 356-364.
4. Liu, C., Yao, J., Mercola, D. and Adamson, E. (2000) The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem, 275, pp. 20315-20323.
5. Shingu, T. and Bornstein, P. (1994) Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J Biol Chem, 269, pp. 32551-32557.
6. Redondo-Munoz, J., Escobar-Diaz, E., Samaniego, R., Terol, M. J., Garcia-Marco, J. A. and Garcia-Pardo, A. (2006) MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood, 108, pp. 3143-3151.
7. Kelly, B. D., Hackett, S. F., Hirota, K., Oshima, Y., Cai, Z. Berg-Dixon, S. et al. (2003) Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res, 93, pp. 1074-1081.
8. Moon, Y., Bottone Jr, F. G., McEntee, M. F. and Eling, T. E. (2005) Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol Cancer Ther, 4, pp. 1551-1558.
9. Kim, S. O., Kwon, J. I., Jeong, Y. K., Kim, G. Y., Kim, N. D. and Choi, Y. H. (2007) Induction of Egr-1 is associated with anti-metastatic and anti-invasive ability of beta-lapachone in human hepatocarcinoma cells. Biosci Biotechnol Biochem, 71, pp. 2169-2176.
10. Steins, M. B., Bieker, R., Padro, T., Kessler, T., Kienast, J. Berdel, W. E. et al. (2003) Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma, 44, pp. 1489-1493.
11. Chanan-Khan, A. and Porter, C. W. (2006) Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol, 7, pp. 480-488.
12. Raza, A., Mehdi, M., Mumtaz, M., Ali, F., Lascher, S. and Galili, N. (2008) Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer, 113, pp. 1596-1604.
13. Lin, Y. C., Shun, C. T., Wu, M. S. and Chen, C. C. (2006) A novel anticancer effect of thalidomide: Inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res, 12, pp. 7165-7173.
14. Chanan-Khan, A. A. and Cheson, B. D. (2008) Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol, 26, pp. 1544-1552.
15. Shin, S. Y., Bahk, Y. Y., Ko, J., Chung, I. Y., Lee, Y. S. Downward, J. et al. (2006) Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras. EMBO J, 25, pp. 1093-1103.
16. Huang, R. P., Fan, Y., de Belle, I., Niemeyer, C., Gottardis, M. M. Mercola, D. et al. (1997) Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer, 72, pp. 102-109.
17. Nair, P., Muthukkumar, S., Sells, S. F., Han, S. S., Sukhatme, V. P. and Rangnekar, V. M. (1997) Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem, 272, pp. 20131-20138.
18. Huang, R. P., Darland, T., Okamura, D., Mercola, D. and Adamson, E. D. (1994) Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. Oncogene, 9, pp. 1367-1377.
19. Lucerna, M., Pomyje, J., Mechtcheriakova, D., Kadl, A., Gruber, F. Bilban, M. et al. (2006) Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res, 66, pp. 6708-6713.
20. Gibbs, J. D., Liebermann, D. A. and Hoffman, B. (2008) Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene, 27, pp. 98-106.
21. Gibbs, J. D., Liebermann, D. A. and Hoffman, B. (2008) Leukemia suppressor function of Egr-1 is dependent on transforming oncogene. Leukemia, 22, pp. 1909-1916.
22. Shafarenko, M., Liebermann, D. A. and Hoffman, B. (2005) Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation. Blood, 106, pp. 871-878.
23. Vidal, F., Aragones, J., Alfranca, A. and de Landazuri, M. O. (2000) Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: Role of transcription factor Egr-1. Blood, 95, pp. 3387-3395.
24. Haas, T. L., Stitelman, D., Davis, S. J., Apte, S. S. and Madri, J. A. (1999) Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem, 274, pp. 22679-22685.
25. Yamaguchi, K., Lee, S. H., Kim, J. S., Wimalasena, J., Kitajima, S. and Baek, S. J. (2006) Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res, 66, pp. 2376-2384.
26. Fuchida, S. I., Shimazaki, C., Hirai, H., Akamatsu, S., Yamada, N. Uchida, R. et al. (2008) The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. Int J Lab Hematol, 30, pp. 220-229.